Editas Medicine Announces Third Quarter 2022 Results and Business Updates

(marketscreener.com) Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2...https://www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Announces-Third-Quarter-2022-Results-and-Business-Updates-42175871/?utm_medium=RSS&utm_content=20221102